PPL-008 conjugates represent potential starting points for the development of co-therapies for resistant melanoma to be administered with an appropriate B-Raf inhibitor in order to overcome B-Raf inhibitor resistance and attenuate ERK activation in melanocytes. Here, BRAF is linked to melanoma.